BUSINESS SUMMARY:
Alfacell Corporation, a development stage company, operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of a class of therapeutic drugs based on its ribonuclease technology for the treatment of cancer, infectious diseases, and other life-threatening conditions. The company focuses primarily on the development of ribonucleases, a family of proteins isolated from the leopard frog. Its product ONCONASE, an amphibian ribonuclease, is in Phase III trial. ONCONASE affects primarily exponentially growing malignant cells. Alfacell also discovered amphinases, a series of proteins, which are bioactive and effective on living cells and organisms, and have both anti-cancer and anti-viral activity. The company was founded by Kuslima Shogen. Alfacell was incorporated in Delaware in 1981 and is based in Bloomfield, New Jersey
ACEL, going on the right path ;)
--- trend is bullish ;) I Might buy it tomorrow if things goes perfect ;) :D ;D Goodluck!!
Too big a market cap and too much hype for a company with 30k of YtoY revenues.
Good short.Even technically there is remarkable resistance around $4.When nas sideways, good temporary play.
Give me some love.... give me some love baby!!!!!! ;) :D ;D
**bought @ $3.67**
Sold ACEL @ 4.55.. 23.98% profit
ACEL currently up 30.00%, I hope you guys made some dollars... ;)
i'll be back @ pullback for you ACEL.... right now let's go hunting for best trades ;) :D ;D
Yo Terliso, looks like your re-entry is long overdue. ;)
ONCONASE(R) has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
Wednesday April 18, 8:30 am ET
5 Top Micro-Cap Stocks
By Brian D. Pacampara
April 19, 2007
Drum roll, please...
So without further ado, here are five CAPS stocks sporting four or five stars, with market caps between $100 million and $200 million, that three or fewer professional analysts are covering.
Company
Market Cap (in millions)
Number of CAPS Ratings
Analysts
Current Analyst Recommendation
National Research (Nasdaq: NRCI)
$159
30
One
Hold
GameTech International (Nasdaq: GMTC)
$154
26
Two
Buy
Alfacell (Nasdaq: ACEL)
$119
15
One
Strong Buy
Nicholas Financial (Nasdaq: NICK)
$110
105
Two
One Buy
One Hold
Edgewater Technology (Nasdaq: EDGW)
$110
13
One
Buy
Data from Yahoo! Finance and Motley Fool CAPS (as of 04/18 close)
There she blows. 8)
Thats no breakout, thats a bust out!!! On highest volume ever. Going long tomorrow. ;)
Hmm, I cannot decide which is more attractive, ACEL or AMRN. Tough decision, I only have room to add 1 risky pick to the portfolio at this time. Let me know your opinion on the better choice.
Cheers,